Director/PDMR Shareholding

RNS Number : 7706C

GlaxoSmithKline PLC

19 April 2017

 

GlaxoSmithKline plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms E Walmsley
b)	Position/status	Chief Executive Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £16.47 82.730 (personal contribution) £16.47 204.873 (personal contribution) £16.47 223.059 (personal contribution) £16.47 82.730 (personal contribution) £16.47 204.858 (personal contribution) £16.47 223.045 (personal contribution) £16.47 82.730 (matching shares) £16.47 204.873 (matching shares) £16.47 223.059 (matching shares) £16.47 82.730 (matching shares) £16.47 204.858 (matching shares) £16.47 223.045 (matching shares)
d)	Aggregated information Aggregated volume Price	2,042.590 £16.47
e)	Date of the transaction	2017-04-18
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr R G Connor
b)	Position/status	President, Global Manufacturing & Supply
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £16.47 60.585 (personal contribution) £16.47 139.194 (personal contribution) £16.47 116.145 (personal contribution) £16.47 60.585 (personal contribution) £16.47 116.131 (personal contribution) £16.47 60.585 (matching shares) £16.47 139.194 (matching shares) £16.47 116.145 (matching shares) £16.47 60.585 (matching shares) £16.47 116.131 (personal contribution)
d)	Aggregated information Aggregated volume Price	985.280 £16.47
e)	Date of the transaction	2017-04-18
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr L Debruyne
b)	Position/status	President, Global Vaccines
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £16.47 195.213 (personal contribution) £16.47 195.199 (personal contribution) £16.47 195.213 (matching shares) £16.47 195.199 (matching shares)
d)	Aggregated information Aggregated volume Price	780.824 £16.47
e)	Date of the transaction	2017-04-18
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr S Dingemans
b)	Position/status	Chief Financial Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £16.47 115.556 (personal contribution) £16.47 270.551 (personal contribution) £16.47 202.642 personal contribution) £16.47 115.540 (personal contribution) £16.47 270.537 (personal contribution) £16.47 202.642 (personal contribution) £16.47 115.556 (matching shares) £16.47 270.551 (matching shares) £16.47 202.642 (matching shares) £16.47 115.540 (matching shares) £16.47 270.537 (matching shares) £16.47 202.642 (matching shares)
d)	Aggregated information Aggregated volume Price	2,354.936 £16.47
e)	Date of the transaction	2017-04-18
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr N Hirons
b)	Position/status	SVP, Global Ethics & Compliance
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £16.47 42.420 (personal contribution) £16.47 100.034 (personal contribution) £16.47 73.412 (personal contribution) £16.47 42.420 (personal contribution) £16.47 100.034 (personal contribution) £16.47 73.398 (personal contribution) £16.47 42.420 (matching shares) £16.47 100.034 (matching shares) £16.47 73.412 (matching shares) £16.47 42.420 (matching shares) £16.47 100.034 (matching shares) £16.47 73.398 (matching shares)
d)	Aggregated information Aggregated volume Price	863.436 £16.47
e)	Date of the transaction	2017-04-18
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr S A Hussain
b)	Position/status	President, Global Pharmaceuticals
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £16.47 199.970 (personal contribution) £16.47 236.389 (personal contribution) £16.47 202.908 personal contribution) £16.47 236.389 (personal contribution) £16.47 202.894 (personal contribution) £16.47 199.970 (matching shares) £16.47 236.389 (matching shares) £16.47 202.908 (matching shares) £16.47 236.389 (matching shares) £16.47 202.894 (matching shares)
d)	Aggregated information Aggregated volume Price	2,157.100 £16.47
e)	Date of the transaction	2017-04-18
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr B McNamara
b)	Position/status	CEO, GSK Consumer Healthcare
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	American Depositary Shares ('ADSs') ISIN: US37733W1053
b)	Nature of the transaction	Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 April 2017 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) $41.81 82.979 (personal contribution) $41.81 82.979 (matching shares)
d)	Aggregated information Aggregated volume Price	165.958 $41.81
e)	Date of the transaction	2017-04-18
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr D S Redfern
b)	Position/status	Chief Strategy Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £16.47 67.977 (personal contribution) £16.47 127.311 (personal contribution) £16.47 92.391 (personal contribution) £16.47 67.977 (personal contribution) £16.47 127.311 (personal contribution) £16.47 92.377 (personal contribution) £16.47 67.977 (matching shares) £16.47 127.311 (matching shares) £16.47 92.391 (matching shares) £16.47 67.977 (matching shares) £16.47 127.311 (matching shares) £16.47 92.377 (matching shares)
d)	Aggregated information Aggregated volume Price	1,150.688 £16.47
e)	Date of the transaction	2017-04-18
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms C Thomas
b)	Position/status	SVP, Human Resources
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £16.47 91.499 (personal contribution) £16.47 186.252 (personal contribution) £16.47 139.061(personal contribution) £16.47 91.483 (personal contribution) £16.47 186.252 (personal contribution) £16.47 139.061 (personal contribution) £16.47 91.499 (matching shares) £16.47 186.252 (matching shares) £16.47 139.061 (matching shares) £16.47 91.483 (matching shares) £16.47 186.252 (matching shares) £16.47 139.061 (matching shares)
d)	Aggregated information Aggregated volume Price	1,667.216 £16.47
e)	Date of the transaction	2017-04-18
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr P C Thomson
b)	Position/status	President, Global Affairs
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £16.47 62.146 (personal contribution) £16.47 113.955 (personal contribution) £16.47 87.545 (personal contribution) £16.47 62.146 (matching shares) £16.47 113.955 (matching shares) £16.47 87.545 matching shares)
d)	Aggregated information Aggregated volume Price	527.292 £16.47
e)	Date of the transaction	2017-04-18
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr D E Troy
b)	Position/status	SVP & General Counsel
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	American Depositary Shares ('ADSs') ISIN: US37733W1053
b)	Nature of the transaction	Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 April 2017 on ADSs held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) $41.81 47.220 (personal contribution) $41.81 106.319 (personal contribution) $41.81 88.057 (personal contribution) $41.81 47.220 (personal contribution) $41.81 106.319 (personal contribution) $41.81 88.044 (personal contribution) $41.81 47.220 (matching shares) $41.81 106.319  (matching shares) $41.81 88.057  (matching shares) $41.81 47.220  (matching shares) $41.81 106.319  (matching shares) $41.81 88.044 (matching shares)
d)	Aggregated information Aggregated volume Price	966.358 $41.81
e)	Date of the transaction	2017-04-18
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Dr P J T Vallance
b)	Position/status	President, R&D
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017 on Ordinary Shares held in the Company's 2009 Deferred Annual Bonus Plan.
c)	Price(s) and volume(s)	Price(s) Volume(s) £16.47 134.685 (personal contribution) £16.47 219.092 (personal contribution) £16.47 151.043 (personal contribution) £16.47 134.685 (personal contribution) £16.47 219.092 (personal contribution) £16.47 151.043 (personal contribution) £16.47 134.685 (matching shares) £16.47 219.092 (matching shares) £16.47 151.043 (matching shares) £16.47 134.685 (matching shares) £16.47 219.092 (matching shares) £16.47 151.043 (matching shares)
d)	Aggregated information Aggregated volume Price	2,019.280 £16.47
e)	Date of the transaction	2017-04-18
f)	Place of the transaction	n/a

 

END

 

 

DSHEKLFFDZFBBBF